Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.48 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19328184 | 1.00 | AAK1 (1.00) | AAK1EGFRMAP1LC3BMAP1LC3ACTSL | |
| SCHEMBL1482036 | 0.89 | AAK1 (0.80) | AAK1EGFRCTSBCTSSCTSK | |
| SCHEMBL1479930 | 0.88 | AAK1 (0.78) | AAK1EGFRCTSBCTSSCTSK | |
| SCHEMBL6296452 | 0.85 | AAK1 (0.74) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17493766 | 0.85 | AAK1 (0.74) | AAK1EGFRCTSBCTSSCTSK | |
| SCHEMBL30022338 | 0.84 | AAK1 (0.73) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17493748 | 0.84 | AAK1 (0.72) | AAK1FPR2 | |
| SCHEMBL30134945 | 0.82 | AAK1 (0.69) | AAK1EGFRMAP1LC3BMAP1LC3ACTSL | |
| SCHEMBL2327747 | 0.80 | AAK1 (0.76) | AAK1EGFRCTSBCTSSCTSK | |
| SCHEMBL28445012 | 0.80 | AAK1 (0.65) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | AAK1, NCK1, DAPK2 | AAK1 1/4885EGFR 1126/4885MAP1LC3B 1240/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | AAK1 1/4885EGFR 1126/4885MAP1LC3B 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.